Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

The MERS and SARS epidemics were both coronaviruses which resulted in a high rate of fatal respiratory failure. Reviewing results the acute treatments with antibiotics, steroids and supportive care once patients developed severe pulmonary involvement, all the patients died.Link below of retrospective review showed all the MERS patients admitted to a middle eastern hospital ICU died.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839124/

From the IPIX coronavirus Blog PDF page 5 is an exciting article which showed inhaled defensins in an animal model reduced the death rate to zero. 75% of the controls died.

I believe that is why research scientist are looking at Brilacidin. ThePDE3/PED4 inhibition most likely plays a role in this effect. Reducing pulmonary inflammation and fibrosis may be the key to treating these critically ill patients.
https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e59c166b728573d1b54f8dc/1582940526011/IPIX+Brilacidin+Defensin+Mimetics+-+COVID-19+Overview+Feb+2020+10pg+final.pdf

If the Brilacidin for coronavirus effectiveness is confirmed with in vitro testing at the biologic testing centers I would not be surprised to see Brilacidin in 2 arms in the subsequent FDA trials ,1 as an aerosol and a second IV infusion.

The aersol approval might open the door to Brilacidin aerosol for a number of pulmonary conditions:
asthma, COPD, cystic fibrosis,bronchiectasis, chronic bronchitis perhaps even inflammatory scarring disorders such as pulmonary fibrosis and pneumonconiosis.

It could be a bigger market than the GI market and if the government and if FDA facilitate the study it may be at little to no cost.

We will have to wait and see

GLTA and JMO,Farrell